Skip to Content

Our Pipeline

We are building a pipeline of in vivo and ex vivo therapies, as well as continuing to develop innovative modular platform capabilities.

In Vivo Program

In Vivo CRISPR is the therapy

Genetic Diseases
Program
Research
IND-Enabling
Early-Stage Clinical
Late-Stage
Clinical
Partners
NTLA-2001 Transthyretin (ATTR)
Amyloidosis
NTLA-2002 Hereditary
Angioedema
NTLA-3001 AATD-Lung
Disease
Hemophilia A / B
Hemophilia A program is in the research stage
Research Programs
Research Programs
  • AATD: alpha-1 antitrypsin deficiency
  • Lead refers to lead development and commercial party
  • * Intellia is advancing both wholly-owned and partnered programs.
Ex Vivo Program

Ex Vivo CRISPR creates the therapy

Immuno-Oncology / Autoimmune Disease
Program
Research
IND-Enabling
Early-Stage Clinical
Late-Stage
Clinical
Partners
Research Programs
  • * Intellia is advancing both wholly-owned and partnered programs.

Download
our pipeline